Bristol Myers Squibb (BMS) has announced positive interim results from the Phase III SUCCESSOR-2 trial evaluating its oral cereblon E3 ligase modulator (CELMoD), mezigdomide, in combination with carfilzomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma (r/rMM). The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard carfilzomib + dexamethasone regimen. The safety profile was consistent with the known characteristics of the drugs. This marks the first positive Phase III outcome for mezigdomide and the second for BMS's CELMoD platform.

Detailed data from the SUCCESSOR-2 trial will be presented at a future medical conference and submitted to health authorities. BMS highlighted that the results reinforce the value of its targeted protein degradation (TPD) platform and the potential of oral therapies for patients with difficult-to-treat blood cancers. MM remains a challenging disease with high unmet need, particularly for patients who relapse after or are refractory to standard therapies.

PharmCube's NextBiopharm® database shows that the candidate is also in early-stage development for two leukaemia indications. Click here to request a free trial for NextBiopharm®.